bioRxiv · 10.1101/2025.01.01.630988
GPNMB is a biomarker for lysosomal dysfunction and is secreted via LRRK2-modulated lysosomal exocytosis
Abstract
Genome-wide association studies have identified Glycoprotein Nmb (GPNMB) as a risk factor for Parkinsons Disease. The risk allele increases GPNMB transcription and GPNMB protein levels in the CSF highlighting GPMNB as a potential biomarker for Parkinsons Disease. However, a lack of knowledge of GPNMBs function and mechanism of secretion have hindered an interpretation of secreted GPNMB levels. In this study, we assessed the mechanism of GPNMB secretion by macrophages, the primary cell type expressing GPNMB in the brain. We show that GPNMB is secreted in response to lysosomal stress via lysosomal exocytosis and highlight the Parkinsons Disease risk factor LRRK2 as a strong modulator of GPNMB secretion.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Bogacki, E. C., Longmore, G., Lewis, P. A., Herbst, S.. 2025-01-01. GPNMB is a biomarker for lysosomal dysfunction and is secreted via LRRK2-modulated lysosomal exocytosis. https://doi.org/10.1101/2025.01.01.630988
Cite the original work for its findings. Save a collection to share your selection of sources.